Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025)
EXCLI Journal · 21.10.2025 · 24 · 1397-1399
DOI: 10.17179/excli2025-8694 ↗Kurz gefasst
Leserbrief in der Zeitschrift EXCLI Journal, online erschienen am 21.10.2025. Verfasst von Abdullah Saad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sindh Medical College, Jinnah Sindh Medical University, Karachi 75510, Pakistan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) represents the most aggressive form of primary brain tumors, characterized by high recurrence rates, poor prognosis, and limited therapeutic options. Standard-of-care treatments, including surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, provide only modest survival benefits due to the rapid development of resistance mechanisms. This clinical challenge underscores the urgency for novel therapeutic strategies aimed at overcoming these resistance pathways and improving patient outcomes. In this context, Tsai et al. (2025) have presented an insightful study demonstrating the potential of Gboxin, an oxidative phosphorylation (OXPHOS) inhibitor, in attenuating TMZ resistance in GBM. The metabolic heterogeneity and adaptability of GBM contribute significantly to its therapeutic resistance (
Autor:innen und Institutionen
- Sindh Medical College, Jinnah Sindh Medical University, Karachi 75510, Pakistan.
Zitieren
APA
Saad, A., & Khan, R. (2025). Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025). EXCLI Journal, 24, 1397-1399. https://doi.org/10.17179/excli2025-8694
Vancouver
Saad A, Khan R. Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025). EXCLI Journal. 2025;24:1397-1399. doi:10.17179/excli2025-8694
BibTeX
@article{Saad2025,
author = {Saad, Abdullah and Khan, Rameen},
title = {Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025)},
journal = {EXCLI Journal},
year = {2025},
volume = {24},
pages = {1397--1399},
doi = {10.17179/excli2025-8694}
}
EUVIMED